IKSUDA THERAPEUTICS
Iksuda Therapeutics (Iksuda) is the developer of a new generation antibody drug conjugates (ADCs).
IKSUDA THERAPEUTICS
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2007-01-01
Address:
Newcastle Upon Tyne, Newcastle Upon Tyne, United Kingdom
Country:
United Kingdom
Website Url:
http://www.iksuda.com
Total Employee:
11+
Status:
Active
Contact:
+44 0191 6031680
Email Addresses:
[email protected]
Total Funding:
51.98 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Google Maps Microsoft Azure DNS Google Maps API Cloudflare DNS MailChimp AddThis Google Maps For Work
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Bicycle Therapeutics
Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Celligenics
Celligenics is a biotechnology company specialized in the development of relevant solutions through stem cell technology.
Raze Therapeutics
Raze Therapeutics, Inc., a biotechnology company, engages in the discovery and development of oncology therapeutics.
Sensei Biotherapeutics
Sensei Biotherapeutics is a clinical-stage biotechnology company specializing in the field of next-generation cancer immunotherapies.
TreeFrog Therapeutics
TreeFrog Therapeutics is a stem cell company that will enable millions of patients to access the medical revolution of cell therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Premier Partners
Premier Partners investment in Series A - Iksuda Therapeutics
Mirae Asset Capital
Mirae Asset Capital investment in Series A - Iksuda Therapeutics
Celltrion
Celltrion investment in Series A - Iksuda Therapeutics
North East Technology Fund
North East Technology Fund investment in Venture Round - Iksuda Therapeutics
IP Group
IP Group investment in Venture Round - Iksuda Therapeutics
IP Group
IP Group investment in Venture Round - Iksuda Therapeutics
Official Site Inspections
http://www.iksuda.com Semrush global rank: 8.95 M Semrush visits lastest month: 227
- Host name: 172.67.193.31
- IP address: 172.67.193.31
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Iksuda Therapeutics"
Iksuda Therapeutics – Creating class-leading ADCs
Iksuda Therapeutics is creating class leading ADCs with enhanced tumor specificity for hard-to-treat cancers. We are building a pipeline of ADC programs centered around tumor-selective delivery of the most relevant payload for any …See details»
Our Purpose - About us - Iksuda
Iksuda Therapeutics is creating class leading ADCs with enhanced tumor specificity for hard-to-treat cancers. We are building a pipeline of ADC programs centered around tumor-selective delivery of the most relevant payload for any …See details»
Our history - About us - Iksuda
Iksuda’s mission was to design and develop class-leading, next generation ADCs, with the potential for clinically meaningful differentiation over in-clinic and on-market comparators. In 2020, through its partnership with LegoChem …See details»
Iksuda Therapeutics - Crunchbase Company Profile
Organization. Iksuda Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Iksuda Therapeutics is a biotechnology company specializing in the …See details»
Iksuda Therapeutics - LinkedIn
Iksuda Therapeutics | 3,541 followers on LinkedIn. Creating class-leading ADCs with enhanced tumor specificity | Through our highly experienced ADC Research & Development Team, we are building a ...See details»
Iksuda Therapeutics Company Profile 2024: Valuation, Funding ...
Iksuda Therapeutics’s primary industry is Drug Discovery. Is Iksuda Therapeutics a private or public company? Iksuda Therapeutics is a Private company. What is Iksuda Therapeutics’s …See details»
Iksuda Therapeutics Ltd - VentureRadar
Iksuda Therapeutics specializes in the development of class-leading Antibody-Drug Conjugates (ADCs) designed for maximum anti-cancer impact and market-leading therapeutic index. The …See details»
Iksuda Therapeutics Enters License Agreement With …
Oct 13, 2020 Iksuda has demonstrated the potential value of prodrug approaches for targeted cancer therapeutics through its recent license of a CD19-targeting ADC from LegoChem Biosciences (“LCB”) for hard ...See details»
Iksuda Therapeutics Deepens Clinical Pipeline Through …
Jan 10, 2022 Iksuda Therapeutics Dave Simpson, Chief Executive Officer Tel: +44 (0) 191 6031680 Email [email protected] FTI Consulting (Financial Media and IR) Simon Conway / Rob Winder Tel: +44 (0) 020 3727 ...See details»
Leading ADC innovation - About us - Iksuda
Iksuda Therapeutics is creating class leading ADCs with enhanced tumor specificity for hard-to-treat cancers. We are building a pipeline of ADC programs centered around tumor-selective delivery of the most relevant payload for any …See details»
Forging stable relationships for antibody-drug …
Iksuda Therapeutics develops next-generation antibody-drug conjugate (ADC) therapies to target cancers that are difficult to treat, or resistant to current treatments, without damaging healthy ...See details»
Iksuda raises $47M to take CD19 antibody-drug conjugate into clinic
Jun 7, 2021 Iksuda Therapeutics has raised $47 million to take a CD19-targeted antibody-drug conjugate (ADC) into the clinic. The British biotech has ceded a big head start to CD19 ADC …See details»
Iksuda Therapeutics Closes $47 Million Financing Round
Jun 7, 2021 Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, said: “This is a transformational investment milestone for Iksuda, enabling us to focus on the progression of …See details»
Iksuda Therapeutics closes $47 million financing round
Newcastle, UK, 7 June 2021: Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced it has …See details»
Our ADC Experts - About us - Iksuda
Iksuda Therapeutics is creating class leading ADCs with enhanced tumor specificity for hard-to-treat cancers. We are building a pipeline of ADC programs centered around tumor-selective …See details»
Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing ...
Jan 10, 2022 NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic …See details»
Iksuda Therapeutics - Announces first patient dosed in Phase 1 …
Newcastle, UK, 23 October 2023: Iksuda Therapeutics (Iksuda), the developer of class leading antibody drug conjugates (ADCs) with enhanced tumour specificity, today announces that the …See details»
Iksuda Therapeutics closes $47 million financing round
The funding will support the advancement of Iksuda’s lead ADC assets and expansion of its payload and conjugation platform technologies. Iksuda’s lead pre-clinical candidate, IKS03, is …See details»
Iksuda Therapeutics announces first patient dosed in Phase 1 trial …
Oct 23, 2023 Iksuda Therapeutics Dave Simpson, Chief Executive Officer Tel: +44 (0) 191 6031680 Email [email protected] FTI Consulting (Financial Media and IR) Simon Conway / …See details»
News & Views - Iksuda
Iksuda Therapeutics is creating class leading ADCs with enhanced tumor specificity for hard-to-treat cancers. We are building a pipeline of ADC programs centered around tumor-selective …See details»